483 Holds up U.S. Expansion for India’s Second-Largest Drugmaker

Drug Industry Daily
A A
Lupin’s plans to expand its sales in the U.S. market have been delayed as the result of Form 483 citations at its facility in Goa, India.

To View This Article:

Login

Subscribe To Drug Industry Daily